Beijing Yunling Biotechnology Co., Ltd, Beijing, China.
Division of HIV/AIDS and Sex-transmitted Virus Vaccines, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China.
Adv Exp Med Biol. 2023;1407:299-312. doi: 10.1007/978-981-99-0113-5_16.
Members of the genus Alphavirus are mostly mosquito-borne pathogens that cause disease in their vertebrate hosts. Chikungunya virus (CHIKV), which is one member of the genus Alphavirus [1], has been a major health problem in endemic areas since its re-emergence in 2006. CHIKV is transmitted to mammalian hosts by the Aedes mosquito, causing persistent debilitating symptoms in many cases. At present, there is no specific treatment or vaccine. Experiments involving live CHIKV need to be performed in BSL-3 facilities, which limits vaccine and drug research. The emergence of pseudotyped virus technology offered the potential for the development of a safe and effective evaluation method. In this chapter, we review the construction and application of pseudotyped CHIKVs, the findings from which have enhanced our understanding of CHIKV. This will, in turn, enable the exploration of promising therapeutic strategies in animal models, with the ultimate aim of developing effective treatments and vaccines against CHIKV and other related viruses.
属的成员黄病毒主要是蚊媒病原体，在脊椎动物宿主中引起疾病。基孔肯雅病毒（CHIKV），属黄病毒的一个成员[1]，自 2006 年重新出现以来，一直是流行地区的一个主要健康问题。CHIKV 通过埃及伊蚊传播给哺乳动物宿主，在许多情况下导致持续的衰弱症状。目前，尚无特定的治疗方法或疫苗。涉及活 CHIKV 的实验需要在 BSL-3 设施中进行，这限制了疫苗和药物的研究。假型病毒技术的出现为开发安全有效的评估方法提供了可能。在本章中，我们回顾了假型 CHIKV 的构建和应用，这些发现增强了我们对 CHIKV 的认识。这反过来又将使我们能够在动物模型中探索有前途的治疗策略，最终目的是开发针对 CHIKV 和其他相关病毒的有效治疗方法和疫苗。
